Xeris Pharmaceuticals Inc., of Chicago, priced a public offering of 5.88 milion shares at $10 each for gross proceeds of $58.8 million. Underwriters, including Jefferies, SVB Leerink, RBC Capital Markets and Mizuho Securities, have an overallotment option for 882,000 shares. Xeris, a specialty pharmaceutical company, is leveraging its technology to develop and commercialize injectable and infusible drug formulations.